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A best evidence topic was written according to a structured protocol. In [patients with acute colonic
pseudo-obstruction] is [neostigmine] superior to [conservative treatment] with respect to [duration of
symptoms and complications]. In total 51 papers were found using the reported search, and ten of these
represented the best evidence to answer the clinical question. The authors, date, journal, study type,
population, main outcomemeasures and results are tabulated.We conclude that intravenous neostigmine
is associated with signiﬁcantly reduced duration of acute colonic pseudo-obstruction (ACPO) compared to
conservative treatment alone. Neostigmine infusion should be administered with continuous cardiac
monitoring for possible bradycardia, which may require treatment with atropine. Seven prospective
analyses and one retrospective study showed that intravenous neostigmine reduces time to resolution of
clinical and radiological features of ACPO. One prospective study showed that neostigmine is only effective
in improving duration of ACPO when it is combined with proponalol. One prospective study showed no
difference in time to resolution of ACPO between neostigmine and conservative treatment but this study
was limited by small sample size, lack of radiological examinations and poor reporting of adverse effects. In
four separate studies patients experienced bradycardia with intravenous neostigmine and this required
treatment with atropine. No other signiﬁcant adverse effects were reported. Overall, intravenous
neostigmine is associated with a signiﬁcant reduction in duration of ACPO. In addition to regularly
reviewing patients for antic-cholinergic side effects, patients should undergo continuous cardiac moni-
toring for bradycardia. Thewide variety inmethodology andmeasurement of outcomes reinforce the need
for higher power studies to improve patient selection and monitoring of outcomes.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A best evidence topic was constructed according to a structured
protocol. The protocol is fully described in the International Journal
of Surgery.12. Three-part question
In [patients with acute colonic pseudo-obstruction] is
[neostigmine] superior to [conservative treatment] with respect to
[duration of symptoms and complications].d Cancer, Imperial College, St
Tel.: þ44 (0) 20 331 21012;
Kayani), manoszacharakis@
ciates Ltd. Published by Elsevier Lt3. Clinical scenario
A patient develops clinical and radiological features suggestive
of acute colonic pseudo-obstruction (ACPO) following a total hip
replacement. The Orthopaedic Consultant asks whether or not you
would consider giving intravenous neostigmine to reduce duration
of symptoms and risk of colonic perforation. You decide to search
the literature to determine if there are any signiﬁcant differences in
duration of symptoms and complications in ACPO treated with
conservative management and intravenous neostigmine.
Pharmacological treatment of ACPO is based on the theory that
reduced colonic peristalsis is caused by excessive sympathetic
stimulation, parasympathetic dysfunction, or a combination of
both. Neostigmine is a reversible acetylcholinesterase inhibitor that
promotes pre and post-synaptic parasympathetic activity at the
ganglion cells of Auerbach’s plexus and smooth muscle ﬁbres,
respectively. This leads to rapid restoration of colonic peristalsis
and resolution of ACPO.d. All rights reserved.
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AMedline search from January 1950 to July 2012 was performed
using OVIDSP interface (exp pseudo-obstruction? OR ileus.mp OR
Ogilvie’s syndrome.mp) AND (exp neostigmine treatment? OR
neostigmine.mp). References were also retrieved from key articles
and reviewed (Fig. 1).
5. Search outcome
Literature search identiﬁed 51 articles. Thesewere reviewed and
ten articles were identiﬁed that provided the best answer to the
question. These articles are presented in Fig. 2.
Ponec et al.2 conducted a prospective, randomised trial on
patients with ACPO secondary to a range of medical and surgical
conditions treated with neostigmine (n ¼ 11) or normal saline
(n ¼ 10). Rapid colonic decompression occurred in 10 of the 11
(91%) patients treated with neostigmine, compared to only 1 in 10
(10%) patients of the placebo group. Two (18%) patients had
symptomatic bradycardia requiring atropine. This study was small
in size and interval cardiac monitoring may have underestimated
asymptomatic bradycardia.
Hallerback et al.3 conducted a prospective, randomised study on
patients with ACPO following open cholecystectomy. Patients were
treated with neostigmine and propranolol (n ¼ 16), neostigmine
(n ¼ 18) or were placebo-treated controls (n ¼ 17). Mean time to
passage of stools was signiﬁcantly reduced with neostigmine and
propanol compared to the control group (68 6 min vs 90 7min,
P< 0.01). Neostigmine alone did not impact duration of symptoms.
In this study, ACPO was assumed in all post-operative patients
without any clinical or radiological conﬁrmation of symptoms.
Myrhoj et al.4 conducted a prospective, randomised trial in
which patients with ACPO following laparotomy were treated with
neostigmine (n ¼ 42) or isotonic saline (n ¼ 44). There was no
signiﬁcant in time to passage of ﬂatus or stool between the
neostigmine (n¼ 8, 19) and placebo groups (n ¼ 15, 34%). However,
in this study, progression and resolution of APCO was not assessed
with imaging and relatively low doses of neostigmine were also
administered.
Mehta et al.5 conducted a prospective study in which ACPO
refractory to conservative management was treated with neostig-
mine (n ¼ 18). Initial response was seen in 16 patients (84%) and
a sustained response in 10 patients (63%). Electrolyte imbalance,
anti-motility agents and post-operative phasewere associated withLiterature Search: 126 
77 papers excluded after 
review of title and abstracts
74 Articles rema
3 studies on patients in which criteria for 
resolution of ACPO not defined 56 articles ex
review of ful
exclusion cri
11 Articles rema
Fig. 1. Flow diagram showing the selection process of studies intoreduced response to neostigmine. Two patients (11%) required
atropine for bradycardia. There was no control group and limited
data presented on comorbidities and medications.
Paran et al.6 conducted a prospective study on 11 patients with
various medical and surgical conditions developing ACPO, which
was treated with neostigmine. Satisfactory clinical and radiological
resolution of ACPO occurred in eight patients (73%) after one dose
and in two patients (18%) after two doses of neostigmine. One
patient (9%) required endoscopic decompression. There was no
signiﬁcant bradycardia reported. In this study, sample size was
small and there was no control group.
Stephenson et al.7 conducted a prospective study on 12
consecutive patients with ACPO treated with intravenous neostig-
mine. Patients were admitted for a range of medical illnesses and
surgical procedures. Satisfactory resolution of ACPO was observed
in 11 of the 12 patients (92%). There were no signiﬁcant adverse
effects observed. There was no control group and patients received
varying doses and rates of neostigmine.
Trevisani et al.8 conducted a prospective study on patients
(n¼ 28) with clinical and radiological features of ACPO treatedwith
neostigmine. All patients were admitted for major medical illness
or surgical procedure. Complete resolution of ACPO occurred in 26
patients (93%), with time to passage of ﬂatus varying from
30 seconds to ten minutes. No signiﬁcant adverse effects were re-
ported. There was no control group and limited data on patient’s
concurrent medical therapy.
Turegano-Fuentes et al.9 conducted a prospective study on 18
patients with ACPO treated with neostigmine. Rapid colonic
decompression was observed in 12 patients (75%) after an initial
dose, and in one patient (6%) after two-doses. One patient (6%) had
bradycardia not requiring atropine. Patients had variable periods of
conservative treatment prior to neostigmine and all received
contrast enema, which may impacted bowel motility.
Hutchinson and Grifﬁths10 conducted a prospective study on 11
patients with ACPO refractory to 48 hours of conservative treat-
ment. Patients were treated with guanethidine and neostigmine.
Eight of the 11 patients (73%) responded with passage of faeces/
ﬂatus and improvement in clinical symptoms. There was no control
group and radiological progress following treatment was not
assessed.
Loftus et al.11 conducted a retrospective study comparing
outcomes in ACPO treated with neostigmine (n ¼ 18) and conser-
vative therapy (n ¼ 16). Rapid clinical and radiological resolution of
ACPO occurred in 16 of the 18 patients (89%), and a sustainedArticles
ining after selection process
25 articles selected from references 
4 studies included patients who received 
other prokinetic agents with IV 
neostigmine (Eg: Polyethylene glycol, 
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cluded after 
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the BET on the use of neostigmine in the treatment of ACPO.
Author, date, 
journal and 
country
Study type 
(Level of 
evidence)
Patient group Outcomes Key results Comments
Ponec et al, 1999
The New England 
Journal of 
medicine, USA 
[2]
Prospective, 
randomised, 
double-blinded 
trial (level 2)
Patients with ACPO not 
responding to 24h of 
conservative treatment 
randomly assigned to 
receive 2mg intravenous 
neostigmine (n=11) or 
saline (n=10).
Clinical response, 
abdominal circumference, 
and measurements of colon 
were measured on 
radiograph.
Colonic decompression
Adverse effects 
Ten of the 11 patients who received neostigmine 
had rapid colonic decompression, compared to 
one of ten patients in the placebo group 
(P<0.001).
Seven in the placebo group and one in the 
neostigmine group without an initial response 
received further dose of neostigmine: all had 
prompt colonic decompression.
Symptomatic bradycardia developed in two 
patients, which required treatment with atropine. 
Rapid colonic decompression with 
neostigmine. Repeat infusion in 
patients without an initial response 
lead to resolution of symptoms. 
Limitations: Small study size, 
intermittent cardiac monitoring 
may have underestimated cardiac 
effects and limited data on other 
post-operative complications. This 
study used abdominal 
circumference to measure 
resolution of ACPO which may be 
unreliable.
Hallerback et al, 
1987
Scand J 
Gastroenterol, 
Sweden. [3]
Prospective, 
randomised, 
double-blinded
trial (level 2)
Prospective trial on 
patients with ACPO 
following 
cholecystectomy. Patient 
randomly assigned to one 
of three groups: 
i. 10mg IV Propanolol &
0.5mg SC Neostigmine 
(n=16)
ii. 0.5mg SC Neostigmine 
(n=18),
iii. placebo-controlled 
(n=17). 
(SC-Subcutaneous, IV-
Intravenous)
Time to passage of stool 
from operation used to 
determine duration of 
ACPO.
Colonic decompression
Adverse effects
Treatment with propranolol and neostigmine 
significantly improved time to resolution of 
ACPO compared to controls (P<0.01). This 
effect was not seen with neostigmine alone.
Propranolol and neostigmine were effective in 
patients older than 60 years (p<0.01) but not in 
younger patients.
Significant bradycardia in propranolol and 
neostigmine group compared to control group 
(p<0.005). No other significant adverse effects.
Reduced duration of ACPO with 
propranolol and neostigmine 
compared to controls in patients 
over 60 years of age. 
Propnaolol and neostigmine 
increased risk of bradycardia
compared to controls.   
Limitations: All patients assumed 
to have post-operative ileus, 
mechanical obstruction not 
excluded radiologically and no 
post-treatment radiographs. In this 
study, a relatively low dose of 
neostigmine was given 
subcutaneously and reduced 
ACPO symptoms only when 
neostigmine was combined with 
propanolol 
Myrhoj et al, 
1988
Dis Colon 
Rectum,
Denmark [4]
Prospective, 
double blinded 
trial
(level 2)
Prospective study on 
patients with ACPO 
following laparotomy. 
Patients randomly assigned 
to receive intravenous 
neostigmine (n=42) or 
normal saline as placebo 
(n=44). 
Treatment administered 
every three hours on the 
third day after laparotomy. 
Colonic decompression No significant difference between neostigmine 
and placebo groups with respect to duration of 
ACPO. 
Neostigmine does not impact time 
to resolution of APCO following 
laparotomy.
Limitations: Adverse effects not 
reported and mechanical 
obstruction not excluded. In this 
study, small neostigmine doses
were given intermuscularly, and 
radiological examinations were 
not used to confirm diagnosis or
assess treatment.  
Mehta et al, 2002
Journal of 
Gastroenterology 
and Hepatology, 
India. [5]
Prospective non-
randomised trial 
(level 3)
Prospective study in 
patients (n=27) with ACPO 
treated with intravenous 
neostigmine. All patients 
refractory to 24 hours of 
conservative treatment 
with nil orally, intravenous 
fluids, nasogastric tube and 
rectal tube placement. 
Sustained clinical response 
was defined as resolution 
of symptoms and colonic 
dilatation on a plain 
radiograph.
Repeat dose of 
neostigmine administered 
to patients with no initial 
response or relapsed after 
first dose.
Colonic response
Adverse effects
Eight of the 27 (30%) patients had spontaneous 
resolution of symptoms with conservative 
management. 
With neostigmine treatment, 16 (84%) patients 
had an initial response and 10 (63%) patients had 
a sustained response.  Nine patients had a second 
infusion of neostigmine, with five of these 
patients having resolution of symptoms. 
Neostigmine responders were more likely to be 
postoperative patients (73%, n=11/15 vs 25%, 
n=1/4, p = 0.07), less likely to have electrolyte 
imbalance (20%, n=3/15 vs 100%, n=4/4, p = 
0.009) and to be on antimotility agents (13%, n= 
2/15 vs 100%, n=4/4, p = 0.003).
Bradycardia in two patients, which required 
atropine for resolution. 
Post-operative patients show good 
response to neostigmine. 
Electrolyte imbalance and anti-
motility agents associated with 
poor response.
Resolution of bradycardia with 
atropine. No other significant 
adverse reactions reported. 
Limitations: No control group and 
use of abdominal distension as 
measure of clinical resolution of 
symptoms unreliable. In this study,
repeat doses of neostigmine were 
given only if 24 hours 
conservative treatment and 24 
hours neostigmine treatment 
failed. Non-responders received 
colonic decompression and 
neostigmine infusion for 30 mins. 
Fig. 2. Table showing the studies used in the best evidence topic paper on the use of neostigmine for resolution of pseudo-obstruction.
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Paran et al, 2000
Journal of the 
American 
College of 
Surgeons, Israel 
[6]
Prospective case 
series (Level 3)
Prospective study on 11 
patients with ACPO treated 
with 2.5mg of neostigmine 
in 100ml of saline for 1 
hour. Patients admitted for 
variety of medical and 
surgical problems. Cardiac 
monitoring throughout 
infusion.
Mechanical obstruction 
excluded by history or 
water-soluble contrast.
Clinical and radiological 
response assessed.  
Colonic decompression
Adverse effects
Clinical and radiological resolution of ACPO in 
8 of the 11 patients (73%) treated with a single 
dose of neostigmine. 
Two patients (18%) required one further infusion 
of neostigmine for resolution of symptoms. 
One patient required colonoscopic
decompression.
No significant adverse complications observed. 
Neostigmine associated with rapid 
resolution of APCO. Repeat 
infusions in non-responders 
improved time to resolution 
symptoms.
Limitations: Small sample size, no 
control group, and use of 
abdominal circumference to 
monitor clinical progress may be 
inaccurate. In this study, no 
attempt was made to decompress 
the colon endoscopically, some 
patients received diagnostic water-
soluble contrast and neostigmine 
was given after only eight hours of 
conservative treatment.
Stephenson et al, 
1994
Dis Colon 
Rectum, UK. [7]
Prospective trial
(level 3)
Prospective study on 12 
patients with contrast-
enema proven ACPO. 
Patients given 2.5mg 
intravenous neostigmine, 
over one to three minutes. 
Repeat infusions if lack of 
response.
All patients underwent 
cardiac monitoring at the 
time of infusion.
Clinical and radiological 
response of ACPO 
monitored 
Colonic decompression
Adverse effects
Satisfactory colonic decompression in 11 out of 
12 patients (92%). 
One patient required right hemi-colectomy for 
incipient caecal perforation.
Reported adverse complications include sweating 
and transient bradycardia, not requiring medical 
treatment. 
Neostigmine treatment in ACPO 
promotes resolution of symptoms 
and can be given safely with low 
incidence of significant adverse 
effects. 
Limitations: Small sample size and
no control group. In this study, 
neostigmine doses varied and 
infusion times varied from 1 to 3 
mins. Rigid sigmoidoscopy was 
performed on all patients but 
decompression was not attempted. 
Trevisani et al, 
2000
Dis Colon 
Rectum, USA. [8]
Prospective trial
(level 3)
Prospective study on 28 
patients with ACPO 
refractory to conservative 
treatment, which included 
nasogastric tube, correction 
of electrolytes and 
withdrawal of anti-
cholinergic and narcotic 
drugs.
Treatment with 2.5mg IV 
neostigmine while being 
monitored with telemetry.
Patients admitted for 
medical and surgical 
problems. 
Diagnosis made on basis of 
clinical and radiological 
findings. 
Colonic decompression
Adverse effects
Immediate relief of ACPO was achieved in 24 of 
the 28 (86%) patients. Complete resolution was 
noted in 26 of the 28 patients (93%). Time to 
passage of flatus varied from 30 seconds to 10 
minutes.
In the two patients who did not respond, one had 
sigmoid cancer which was resected and the other 
died of multi-organ failure.
Adverse effects of abdominal cramps, nausea, 
light-headedness and sweats were reported. No 
serious adverse effects requiring atropine were 
reported.
Neostigmine associated with rapid 
resolution of ACPO without any 
significant adverse effects. 
Mechanical obstruction and 
critical illness correlated with poor 
response to neostigmine.
Limitations: No control groups or 
matching of patients for 
medications affecting bowel 
kinesia or co-morbidities. In this 
study, duration of conservative 
management is unclear and all 
anticholinergic and narcotic drugs 
were stopped. Also, all patients 
underwent diagnostic water-
soluble contrast enema or 
sigmoidoscopy, unless negative 
colonocscopy was performed 
within last six months,
Turegano-Fuentes 
et al, 1997
Dis Colon 
Rectum, Spain. 
[9]
Prospective trial
(level 3)
Prospective study on 16 
patients with ACPO 
admitted for various 
medical and surgical 
conditions. 
Patients received varying 
duration of conservative 
treatment (hours to days). 
Treatment protocol 
consisted of 2.5mg 
intravenous neostigmine
over 60 mins. 
Clinical and radiological 
response to neostigmine 
monitored. 
Colonic decompression
Adverse effects
Rapid clinical and radiological decompression of 
the colon observed in 12 patients (75%) after a 
single dose.
One patient had complete resolution after a 
second dose, and the remaining three patients 
only had partial resolution.
One patient experienced bradycardia, which 
resolved with discontinuation of the neostigmine 
infusion. Atropine was not required.
Authors comment that patients 
diagnosed with clinical and 
radiological diagnosis of ACPO 
should be treated with intravenous 
neostigmine provided there is no 
contraindication. 
No significant adverse 
complications. 
Limitations: Small sample size 
and no control group. In this study,
there were significant variations in 
duration of conservative treatment 
prior to neostigmine. The second 
dose of neostigmine was given 
after only three to fours hours of 
failing to respond to initial dose. 
Hutchinson et al, 
1992
Prospective study on 11 
patients with ACPO not 
responding to 48h of 
Colonic decompression In eight of the 11 patients (73%), there was rapid 
passage of flatus and/or faeces with clinical 
improvement in distension. There was no 
No change observed during 
guanethidine phase of treatment. 
Rapid and effective resolution of 
Fig. 2. (continued).
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Ann Royal Coll 
of surg, UK. [10]
Prospective trial
(level 3)
conservative treatment. 
Patients treated with 20mg 
IV guanethidine over 40 
mins and 2.5mg IV 
intravenous neostigmine
over 1 min.  
All patients had emergency 
contrast enema 
examination to exclude 
mechanical obstruction. 
Adverse effects
recurrence of pseudo-obstruction in these 
patients. 
In three patients, neostigmine treatment failed: 
two patients settled with conservative 
management, one patient required colonoscopic 
decompression. 
Postural hypotension noted in one patient, which 
resolved spontaneously.
symptoms with neostigmine 
therapy. 
No serious adverse effects noted. 
Limitations: No control group and 
radiological response to treatment 
not reviewed. In this study, 
patients received guanethidine and 
emergency contrast enema prior to 
neostigmine treatment. Some 
patients also received cisapride 
prior to the study.
Loftus et al, 2002
The American 
Journal of 
Gstroenterology, 
US. [11]
Retrospective 
analysis (level 4)
Retrospective study on 
patients with ACPO treated 
with conservative 
management (n=16) and  
2mg IV neostigmine over 
3-5 mins (n=18). 
All neostigmine patients 
had failed to respond to 
variable durations of 
conservative treatment.
Mechanical obstruction 
excluded by the presence 
of air throughout colon on 
plain radiograph. 
Clinical and radiological 
response to treatment 
assessed. 
Colonic decompression
Adverse effects
Prompt evacuation (<30mins) of faeces or flatus 
in 16 of the 18 patients (89%) who received 
neostigmine.  
Sustained clinical response noted in 11 of 18 
patients (61%). Colonic decompression or 
surgery in remaining seven patients (39%). 
Neostigmine responders more likely to be older 
(mean age, 76 yr vs 54 yr, p=0.03), than non-
responders. Median time to resolution of 
symptoms of ACPO with conservative treatment 
was four days compared to two days in patients 
responding to neostigmine( p=0.038) .
Neostigmine treatment associated with 
bradycardia, abdominal pain, excess salivation, 
and vomiting. Two of the 18 patients (11%) 
required atropine for symptomatic bradycardia.
Neostigmine significantly 
improved time to resolution of 
APCO and reduced need for 
colonic decompression or surgery. 
Female sex and older age 
associated with improved response 
to neostigmine. Increased use of 
narcotics associated with reduced 
response in conservative treatment 
group.
Limitations: Retrospective study, 
no contrast studies or high 
resolution imaging to exclude 
mechanical obstruction. In this 
study, the end points for resolution 
of APCO are not clearly defined
and authors are unsure about doses 
of narcotics at time of neostigmine 
treatment.
Fig. 2. (continued).
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atropine for bradycardia. This was a retrospective studywith poorly
deﬁned endpoints for resolution of ACPO.
6. Clinical bottom level
Existing evidence shows that intravenous neostigminemay help
to signiﬁcantly reduce duration of symptoms in ACPO. Patients with
a transient response to an initial dose of neostigmine may also
beneﬁt from repeat infusions to maintain a sustained response. In
addition to regularly reviewing patients for anti-cholinergic side
effects, continuous cardiac monitoring should be considered for
detection of bradycardia, which may require treatment with atro-
pine. Many of the studies investigating the use of neostigmine in
ACPO are small in size, lack control groups, use variable doses of
neostigmine and do not review radiological response. Further
higher power studies may enable better patient selection and
improved understanding of differences in outcomes.
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